---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-22-000050"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:22:22.069207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%

## Summary
- Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.
- Reported EPS $1.59 (-31.2%); adjusted EPS $2.03 (-1.5%); Biologics and Generics mid-single digit organic growth.
- FY2022 guidance cut: net sales $2.830-2.840B (prior $2.950-2.975B), adjusted EPS $8.15-8.20 (prior $9.00-9.15).
- Dividend raised 5.6% to $0.19/share, payable Nov 16 to holders of record Nov 9; 30th consecutive annual increase.
- Management cited delays in expansion projects and customer mix-shift; expects resolution early 2023; capex guidance lowered to $300-320M.

## SEC filing metadata
- accession: 0000105770-22-000050
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/wst-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-22-000050
- JSON: https://secwatch.observer/filing/0000105770-22-000050.json
- Plain text: https://secwatch.observer/filing/0000105770-22-000050.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.
  - Period: Third-Quarter 2022
  - EPS: 2.03
  - Result: reported results
  source text: (610) 594-3054 Quintin.Lai@westpharma.com Michele.Polinsky@westpharma.com --- EX-99.2 (EX-99.2) --- finalwestq3oct2022 1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M | 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.
  - Period: Third-Quarter 2022
  - EPS: 2.03
  - Result: reported results
  source text: • Adjusted-diluted EPS of $2.03 declined 1.5%. • Company is updating full-year 2022 net sales guidance to a new range of $2.830 billion to $2.840 billion, compared to a prior range of $2.950 billion to $2.975 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.